Auckland – October 05, 2026 -- Aroa Biosurgery Limited (ASX: ARX) reported that its Symphony wound care product achieved a 55% complete closure rate for diabetic foot ulcers within 12 weeks, compared with 35% for standard of care alone, in a peer-reviewed randomized controlled trial published in the International Wound Journal.
Trial enrolled 143 patients across 10 U.S. sites to test Symphony against standard care
The prospective, multicenter RCT randomized patients with Wagner Grade 1 or 2 diabetic foot ulcers to receive either weekly Symphony plus standard of care or standard of care alone, for up to 12 weeks or until complete closure. Ulcers ranged from full-thickness skin wounds to deeper lesions extending into ligaments, tendons, joint capsules or deep fascia.
Symphony reduced mean healing time by 7.8 days
Patients treated with Symphony plus standard of care achieved complete wound closure in a mean of 65.4 days, versus 73.2 days for standard of care alone (p=0.041). The closure rate difference was also statistically significant at p=0.039.
CEO says results strengthen reimbursement and commercial positioning
Aroa CEO Brian Ward said the trial places Symphony among a small group of Cellular, Acellular and Matrix-like Products (CAMPs) with Level I effectiveness data, a distinction he said strengthens the product's differentiation and commercial value proposition amid growing demand from clinicians, payors and reimbursement authorities for robust RCT evidence.
Symphony combines ECM scaffold with high molecular weight hyaluronic acid
Symphony pairs Aroa's extracellular matrix technology with high molecular weight hyaluronic acid (HMWHA), a polymer capable of retaining roughly 1,000 times its weight in water. Aroa states Symphony is the only commercially available CAMP incorporating HMWHA for treating hard-to-heal wounds such as diabetic foot ulcers and venous leg ulcers.
Lead investigator Dr David Armstrong said the trial demonstrates that combining the bioscaffold with HMWHA can significantly improve wound healing when added to good standard of care, giving clinicians evidence to inform treatment decisions.